RUCAPARIB CLINICAL OVERVIEW

UPDATED MAY 2017

Clovis Oncology believes that precision medicine — delivering the right treatment to the right patient — is the future of cancer therapy.

Clovis invests in robust clinical research and development programs targeting specific subsets of cancer populations to better identify the patients who are most likely to benefit from our treatments. We partner to develop companion diagnostics to enable physicians to best guide patients to appropriate treatment.

ABOUT RUCAPARIB

Rucaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. In December 2016, the U.S. Food and Drug Administration approved rucaparib (Rubraca®) to treat advanced ovarian cancer patients who have been treated with two or more chemotherapies and who have a deleterious germline or somatic BRCA mutation.

Clovis is also exploring rucaparib as monotherapy and in combination in solid tumor types with mutant BRCA and HRD populations. In addition to those described below, studies are underway or planned to evaluate rucaparib in breast, pancreatic, gastroesophageal, lung and urothelial cancers.

At Clovis, we are set apart by our belief that a commitment to precision medicine requires a dedication to robust clinical development and sound scientific evidence. This is the guiding force for all clinical programs upon which we embark.

— **Patrick J. Mahaffy**
President and CEO

CURRENT CLOVIS CLINICAL TRIALS INVESTIGATING RUCAPARIB

Trial Name, Phase	Indication	Population	Primary Endpoints	Status
Study 10 Phase 1, 2 *Study info*	Ovarian cancer, treatment setting	Patients with gBRCA mutation ovarian cancer or other solid tumor	• PK profile • Safety profile • Overall response rate	Part 1: Complete Part 2: Ongoing; enrollment completed Data supported 2016 FDA approval; view press release here.
ARIEL2 Phase 2 *Study info*	Ovarian cancer, treatment setting	Patients with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer	• Progression-free survival • Overall response rate	Part 1: Complete Part 2: Ongoing; enrollment completed Data supported 2016 FDA approval; view press release here.
ARIEL3 Phase 3 *Study info*	Ovarian cancer, maintenance treatment setting	Platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer	• Progression-free survival	Ongoing; enrollment completed Data anticipated by late June 2017
ARIEL4 Phase 3 *Study info*	Ovarian cancer, treatment setting	Relapsed, BRCA mutant, high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer	• Progression-free survival	Recruiting
TRITON2 Phase 2 *Study info*	Prostate cancer	Metastatic castration-resistant prostate cancer associated with homologous recombination deficiency following androgen receptor-targeted therapy and taxane-based chemotherapy	• Objective response rate • Prostate specific antigen (PSA) response	Recruiting
TRITON3 Phase 3 *Study info*	Prostate cancer	Metastatic castration-resistant prostate cancer associated with homologous recombination deficiency following androgen receptor-targeted therapy	• Radiographic progression-free survival	Recruiting

Rucaparib is only FDA approved for the indication stated above in the “About Rucaparib” section of this clinical overview. All other disease indications are investigational and therefore have not been proven safe or effective by any health authority.

The above chart reflects all Clovis-sponsored clinical trials. For more information on investigator-sponsored and partner-sponsored clinical trials, please visit www.clovisoncology.com/pipeline.

Visit **www.ClovisOncology.com** to learn more about Clovis Oncology and current rucaparib clinical trials underway. For information about enrollment status for any of these clinical trials, visit **www.ClinicalTrials.gov**.